First author [Ref.] | Treatment/controln | Treatment, follow-upmonths | Outcomes | Comments |
Erkkila 42 | 9 budesonide (800 μg daily)/10 placebo | 2−2.5, 0 | Improvement in serum β2-microglobulin, BALF hyaluronan and lymphocytosis | Newly diagnosed steroid-naive patients |
Milman 44 | 9 budesonide (1200 μg daily)/12 placebo | 12, 6 | No difference | ∼40% of the study population received oral corticosteroids |
du Bois 45 | 21 fluticasone (2000 μg daily)/22 placebo | 6, 7–8 | No difference | ∼75% of the study population received oral corticosteroids |
McGrath 46 | 15 beclometasone (1600 μg daily)/12 placebo | 6, 0 | No difference | No data on oral corticosteroid use reported |
Baughman 47 | 10 fluticasone (1600 μg daily)/11 placebo | 12, 0 | No difference | All patients received prednisone 20 mg·day-1 in the 4 weeks before study entry |
Alberts 48 | 22 budesonide (1200 μg daily)/25 placebo | 6, 6 | Improvement in symptom score and VCI (∼8%) | Newly diagnosed steroid-naive patients |
BALF: bronchoalveolar lavage fluid; VCI: inspiratory vital capacity.